Table 1.
Baseline patient demographics and disease characteristics by stage at diagnosis. ECOG, Eastern Cooperative Oncology Group.
| Variable | Stage II n (%) |
Stage III n (%) |
Stage IV n (%) |
All Patients n (%) |
|---|---|---|---|---|
| Stage at diagnosis * | 27 (11) | 120 (50) | 93 (39) | 241 (100) |
| Sex | ||||
| Female | 13 (48) | 47 (39) | 46 (49) | 107 (44) |
| Male | 14 (52) | 73 (61) | 47 (51) | 134 (56) |
| Age | ||||
| Mean | 40 | 40 | 41 | 40 |
| Median | 40 | 43 | 43 | 42 |
| Range (min–max) | 25–49 | 25–49 | 21–49 | 19–49 |
| <20 | 0 (0) | 1 (<1) | 0 (0) | 1 (<1) |
| 20–29 | 2 (7) | 12 (10) | 10 (11) | 24 (10) |
| 30–39 | 11 (41) | 39 (33) | 28 (30) | 78 (32) |
| 40–49 | 14 (52) | 68 (57) | 55 (59) | 138 (57) |
| Ethnic Background | ||||
| White British | 14 (52) | 77 (64) | 64 (69) | 156 (65) |
| White Irish | 0 (0) | 3 (2) | 1 (1) | 4 (2) |
| White Other | 2 (7) | 8 (7) | 8 (9) | 18 (7) |
| Asian/Asian-British | 2 (7) | 14 (12) | 8 (9) | 24 (10) |
| African/Caribbean/Black British | 4 (15) | 10 (8) | 4 (4) | 18 (7) |
| Mixed/Multiple (Other Mixed) | 1 (4) | 0 (0) | 0 (0) | 1 (<1) |
| Another Ethnic Group | 4 (15) | 8 (7) | 8 (9) | 20 (8) |
| ECOG PS | ||||
| 0 | 12 (44) | 24 (20) | 16 (17) | 52 (22) |
| 1 | 15 (56) | 95 (79) | 68 (73) | 179 (74) |
| 2 | 0 (0) | 1 (1) | 4 (4) | 5 (2) |
| 3 | 0 (0) | 0 (0) | 5 (5) | 5 (2) |
| Location of primary tumor | ||||
| Caecum/ascending colon | 5 (18) | 31 (26) | 21 (23) | 57 (24) |
| Transverse colon | 3 (11) | 10 (8) | 5 (5) | 18 (7) |
| Descending colon/sigmoid | 7 (26) | 26 (22) | 31 (33) | 64 (26) |
| Recto-sigmoid | 1 (4) | 4 (3) | 11 (12) | 16 (7) |
| Rectum | 11 (41) | 49 (41) | 25 (27) | 86 (36) |
| Histology | ||||
| Adenocarcinoma | 23 (85) | 103 (86) | 83 (89) | 210 (87) |
| Mucinous adenocarcinoma | 4 (15) | 16 (13) | 3 (3) | 23 (10) |
| Signet cell | 0 (0) | 1 (1) | 5 (5) | 6 (2) |
| Unknown | 0 (0) | 0 (0) | 2 (2) | 2 (1) |
| Primary Tumor differentiation | ||||
| Well | 1 (4) | 3 (2) | 0 (0) | 4 (2) |
| Moderate | 23 (85) | 93 (78) | 60 (65) | 176 (73) |
| Poor | 3 (11) | 21 (18) | 20 (21) | 45 (19) |
| Unknown | 0 (0) | 3 (2) | 13 (14) | 16 (6) |
| KRAS | ||||
| Mutant | 8 (30) | 18 (15) | 23 (25) | 49 (20) |
| Wild type | 4 (15) | 35 (29) | 46 (50) | 85 (35) |
| Unknown | 15 (55) | 67 (56) | 24 (26) | 107 (44) |
| NRAS | ||||
| Mutant | 0 | 0 | 0 | 0 |
| Wild type | 6 (22) | 31 (26) | 28 (30) | 65 (27) |
| Unknown | 21 (78) | 89 (74) | 65 (70) | 176 (73) |
| BRAF | ||||
| Mutant | 0 (0) | 8 (7) | 4 (4) | 12 (5) |
| Wild type | 6 (22) | 24 (20) | 24 (26) | 54 (22) |
| Unknown | 21 (78) | 88 (73) | 65 (70) | 175 (73) |
| MMR | ||||
| Deficient | 3 (11) | 13 (11) | 1 (1) | 17 (7) |
| Proficient | 22 (82) | 69 (57) | 56 (60) | 148 (61) |
| Unknown | 2 (7) | 38 (32) | 36 (39) | 76 (32) |
| Hereditary Syndromes | ||||
| Lynch syndrome | 3 (11) | 7 (6) | 1 (1) | 11 (5) |
| FAP | 1 (4) | 0 (0) | 0 (0) | 1 (<1) |
| Other | 0 (0) | 3 (3) | 1 (1) | 4 (2) |
* 1 patient had stage I rectal cancer at diagnosis.